Page "Investigational New Drug" Paragraph 0

The United States Food and Drug Administration's Investigational New Drug ( IND ) program is the means by which a pharmaceutical company obtains permission to ship an experimental drug across state lines ( usually to clinical investigators ) before a marketing application for the drug has been approved.

The FDA reviews the IND application for safety to assure that research subjects will not be subjected to unreasonable risk.

If the application is cleared, the candidate drug usually enters a Phase 1 clinical trial.